Cargando…

Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study

OBJECTIVE: To quantify the background incidence rates of 15 prespecified adverse events of special interest (AESIs) associated with covid-19 vaccines. DESIGN: Multinational network cohort study. SETTING: Electronic health records and health claims data from eight countries: Australia, France, German...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xintong, Ostropolets, Anna, Makadia, Rupa, Shoaibi, Azza, Rao, Gowtham, Sena, Anthony G, Martinez-Hernandez, Eugenia, Delmestri, Antonella, Verhamme, Katia, Rijnbeek, Peter R, Duarte-Salles, Talita, Suchard, Marc A, Ryan, Patrick B, Hripcsak, George, Prieto-Alhambra, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group Ltd. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8193077/
https://www.ncbi.nlm.nih.gov/pubmed/35727911
http://dx.doi.org/10.1136/bmj.n1435
_version_ 1783706178341044224
author Li, Xintong
Ostropolets, Anna
Makadia, Rupa
Shoaibi, Azza
Rao, Gowtham
Sena, Anthony G
Martinez-Hernandez, Eugenia
Delmestri, Antonella
Verhamme, Katia
Rijnbeek, Peter R
Duarte-Salles, Talita
Suchard, Marc A
Ryan, Patrick B
Hripcsak, George
Prieto-Alhambra, Daniel
author_facet Li, Xintong
Ostropolets, Anna
Makadia, Rupa
Shoaibi, Azza
Rao, Gowtham
Sena, Anthony G
Martinez-Hernandez, Eugenia
Delmestri, Antonella
Verhamme, Katia
Rijnbeek, Peter R
Duarte-Salles, Talita
Suchard, Marc A
Ryan, Patrick B
Hripcsak, George
Prieto-Alhambra, Daniel
author_sort Li, Xintong
collection PubMed
description OBJECTIVE: To quantify the background incidence rates of 15 prespecified adverse events of special interest (AESIs) associated with covid-19 vaccines. DESIGN: Multinational network cohort study. SETTING: Electronic health records and health claims data from eight countries: Australia, France, Germany, Japan, the Netherlands, Spain, the United Kingdom, and the United States, mapped to a common data model. PARTICIPANTS: 126 661 070 people observed for at least 365 days before 1 January 2017, 2018, or 2019 from 13 databases. MAIN OUTCOME MEASURES: Events of interests were 15 prespecified AESIs (non-haemorrhagic and haemorrhagic stroke, acute myocardial infarction, deep vein thrombosis, pulmonary embolism, anaphylaxis, Bell’s palsy, myocarditis or pericarditis, narcolepsy, appendicitis, immune thrombocytopenia, disseminated intravascular coagulation, encephalomyelitis (including acute disseminated encephalomyelitis), Guillain-Barré syndrome, and transverse myelitis). Incidence rates of AESIs were stratified by age, sex, and database. Rates were pooled across databases using random effects meta-analyses and classified according to the frequency categories of the Council for International Organizations of Medical Sciences. RESULTS: Background rates varied greatly between databases. Deep vein thrombosis ranged from 387 (95% confidence interval 370 to 404) per 100 000 person years in UK CPRD GOLD data to 1443 (1416 to 1470) per 100 000 person years in US IBM MarketScan Multi-State Medicaid data among women aged 65 to 74 years. Some AESIs increased with age. For example, myocardial infarction rates in men increased from 28 (27 to 29) per 100 000 person years among those aged 18-34 years to 1400 (1374 to 1427) per 100 000 person years in those older than 85 years in US Optum electronic health record data. Other AESIs were more common in young people. For example, rates of anaphylaxis among boys and men were 78 (75 to 80) per 100 000 person years in those aged 6-17 years and 8 (6 to 10) per 100 000 person years in those older than 85 years in Optum electronic health record data. Meta-analytic estimates of AESI rates were classified according to age and sex. CONCLUSION: This study found large variations in the observed rates of AESIs by age group and sex, showing the need for stratification or standardisation before using background rates for safety surveillance. Considerable population level heterogeneity in AESI rates was found between databases.
format Online
Article
Text
id pubmed-8193077
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group Ltd.
record_format MEDLINE/PubMed
spelling pubmed-81930772021-06-13 Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study Li, Xintong Ostropolets, Anna Makadia, Rupa Shoaibi, Azza Rao, Gowtham Sena, Anthony G Martinez-Hernandez, Eugenia Delmestri, Antonella Verhamme, Katia Rijnbeek, Peter R Duarte-Salles, Talita Suchard, Marc A Ryan, Patrick B Hripcsak, George Prieto-Alhambra, Daniel BMJ Research OBJECTIVE: To quantify the background incidence rates of 15 prespecified adverse events of special interest (AESIs) associated with covid-19 vaccines. DESIGN: Multinational network cohort study. SETTING: Electronic health records and health claims data from eight countries: Australia, France, Germany, Japan, the Netherlands, Spain, the United Kingdom, and the United States, mapped to a common data model. PARTICIPANTS: 126 661 070 people observed for at least 365 days before 1 January 2017, 2018, or 2019 from 13 databases. MAIN OUTCOME MEASURES: Events of interests were 15 prespecified AESIs (non-haemorrhagic and haemorrhagic stroke, acute myocardial infarction, deep vein thrombosis, pulmonary embolism, anaphylaxis, Bell’s palsy, myocarditis or pericarditis, narcolepsy, appendicitis, immune thrombocytopenia, disseminated intravascular coagulation, encephalomyelitis (including acute disseminated encephalomyelitis), Guillain-Barré syndrome, and transverse myelitis). Incidence rates of AESIs were stratified by age, sex, and database. Rates were pooled across databases using random effects meta-analyses and classified according to the frequency categories of the Council for International Organizations of Medical Sciences. RESULTS: Background rates varied greatly between databases. Deep vein thrombosis ranged from 387 (95% confidence interval 370 to 404) per 100 000 person years in UK CPRD GOLD data to 1443 (1416 to 1470) per 100 000 person years in US IBM MarketScan Multi-State Medicaid data among women aged 65 to 74 years. Some AESIs increased with age. For example, myocardial infarction rates in men increased from 28 (27 to 29) per 100 000 person years among those aged 18-34 years to 1400 (1374 to 1427) per 100 000 person years in those older than 85 years in US Optum electronic health record data. Other AESIs were more common in young people. For example, rates of anaphylaxis among boys and men were 78 (75 to 80) per 100 000 person years in those aged 6-17 years and 8 (6 to 10) per 100 000 person years in those older than 85 years in Optum electronic health record data. Meta-analytic estimates of AESI rates were classified according to age and sex. CONCLUSION: This study found large variations in the observed rates of AESIs by age group and sex, showing the need for stratification or standardisation before using background rates for safety surveillance. Considerable population level heterogeneity in AESI rates was found between databases. BMJ Publishing Group Ltd. 2021-06-14 /pmc/articles/PMC8193077/ /pubmed/35727911 http://dx.doi.org/10.1136/bmj.n1435 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Li, Xintong
Ostropolets, Anna
Makadia, Rupa
Shoaibi, Azza
Rao, Gowtham
Sena, Anthony G
Martinez-Hernandez, Eugenia
Delmestri, Antonella
Verhamme, Katia
Rijnbeek, Peter R
Duarte-Salles, Talita
Suchard, Marc A
Ryan, Patrick B
Hripcsak, George
Prieto-Alhambra, Daniel
Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study
title Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study
title_full Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study
title_fullStr Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study
title_full_unstemmed Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study
title_short Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study
title_sort characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8193077/
https://www.ncbi.nlm.nih.gov/pubmed/35727911
http://dx.doi.org/10.1136/bmj.n1435
work_keys_str_mv AT lixintong characterisingthebackgroundincidenceratesofadverseeventsofspecialinterestforcovid19vaccinesineightcountriesmultinationalnetworkcohortstudy
AT ostropoletsanna characterisingthebackgroundincidenceratesofadverseeventsofspecialinterestforcovid19vaccinesineightcountriesmultinationalnetworkcohortstudy
AT makadiarupa characterisingthebackgroundincidenceratesofadverseeventsofspecialinterestforcovid19vaccinesineightcountriesmultinationalnetworkcohortstudy
AT shoaibiazza characterisingthebackgroundincidenceratesofadverseeventsofspecialinterestforcovid19vaccinesineightcountriesmultinationalnetworkcohortstudy
AT raogowtham characterisingthebackgroundincidenceratesofadverseeventsofspecialinterestforcovid19vaccinesineightcountriesmultinationalnetworkcohortstudy
AT senaanthonyg characterisingthebackgroundincidenceratesofadverseeventsofspecialinterestforcovid19vaccinesineightcountriesmultinationalnetworkcohortstudy
AT martinezhernandezeugenia characterisingthebackgroundincidenceratesofadverseeventsofspecialinterestforcovid19vaccinesineightcountriesmultinationalnetworkcohortstudy
AT delmestriantonella characterisingthebackgroundincidenceratesofadverseeventsofspecialinterestforcovid19vaccinesineightcountriesmultinationalnetworkcohortstudy
AT verhammekatia characterisingthebackgroundincidenceratesofadverseeventsofspecialinterestforcovid19vaccinesineightcountriesmultinationalnetworkcohortstudy
AT rijnbeekpeterr characterisingthebackgroundincidenceratesofadverseeventsofspecialinterestforcovid19vaccinesineightcountriesmultinationalnetworkcohortstudy
AT duartesallestalita characterisingthebackgroundincidenceratesofadverseeventsofspecialinterestforcovid19vaccinesineightcountriesmultinationalnetworkcohortstudy
AT suchardmarca characterisingthebackgroundincidenceratesofadverseeventsofspecialinterestforcovid19vaccinesineightcountriesmultinationalnetworkcohortstudy
AT ryanpatrickb characterisingthebackgroundincidenceratesofadverseeventsofspecialinterestforcovid19vaccinesineightcountriesmultinationalnetworkcohortstudy
AT hripcsakgeorge characterisingthebackgroundincidenceratesofadverseeventsofspecialinterestforcovid19vaccinesineightcountriesmultinationalnetworkcohortstudy
AT prietoalhambradaniel characterisingthebackgroundincidenceratesofadverseeventsofspecialinterestforcovid19vaccinesineightcountriesmultinationalnetworkcohortstudy